Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Novavax (NASDAQ:NVAX) had its price objective hoisted by investment analysts at HC Wainwright from $11.00 to $16.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 57.79% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. B. Riley Financial reaffirmed a “buy” rating and set a $16.00 target price (down from $18.00) on shares of Novavax in a report on Monday, November 10th. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research report on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, January 20th. TD Cowen lowered their target price on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. Finally, Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $11.88.

Novavax Stock Performance

Shares of NVAX stock opened at $10.14 on Friday. Novavax has a 52-week low of $5.01 and a 52-week high of $11.97. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93. The stock has a market cap of $1.65 billion, a PE ratio of 4.21 and a beta of 2.58. The business has a 50-day simple moving average of $8.34 and a 200-day simple moving average of $8.03.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.66) by $0.77. Novavax had a negative return on equity of 836.17% and a net margin of 39.19%.The firm had revenue of $136.40 million for the quarter, compared to analyst estimates of $90.26 million. During the same period last year, the company earned ($0.51) earnings per share. Novavax’s revenue for the quarter was up 66.6% compared to the same quarter last year. On average, equities analysts expect that Novavax will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC lifted its stake in Novavax by 11.0% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 12,755 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 1,268 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Novavax by 1.0% during the third quarter. Legal & General Group Plc now owns 155,743 shares of the biopharmaceutical company’s stock valued at $1,350,000 after acquiring an additional 1,529 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Novavax by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 1,617 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Novavax by 2.3% in the second quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company’s stock worth $492,000 after acquiring an additional 1,718 shares during the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Novavax by 5.5% in the second quarter. SBI Securities Co. Ltd. now owns 34,095 shares of the biopharmaceutical company’s stock worth $215,000 after acquiring an additional 1,766 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Q4 results beat: Novavax reported a surprise GAAP profit (EPS $0.11) and ~67% year‑over‑year revenue growth, driven by licensing/milestone revenues — the core reason the stock jumped on the news. Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
• Positive Sentiment: Strong operational highlights and balance sheet: Full‑year 2025 revenue of ~$1.1B, $225M Sanofi milestones earned, and year‑end cash of ~$751M reduce short‑term financing risk and support pipeline investments. Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• Positive Sentiment: Analyst upgrade: HC Wainwright raised its price target to $16 and kept a Buy rating, signaling bullish conviction from at least one sell‑side shop. Benzinga
• Neutral Sentiment: Investor access: Management will present at upcoming investor conferences (TD Cowen fireside chat, others) — useful for transparency but not a near‑term catalyst by itself. Novavax to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Market activity: Unusual options flow showed heavy call buying around the earnings move, indicating elevated short‑term speculative interest. (This reflects trader positioning, not fundamental change.)
• Neutral Sentiment: Earnings call transcript posted for deeper detail on results and guidance assumptions. Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: 2026 revenue guidance disappointed relative to consensus: Management guided revenue of $230M–$270M for 2026, well below street estimates (~$402M), creating concern about demand trends and prompting profit‑taking. Novavax Q4 Press Release / Guidance
• Negative Sentiment: Analyst caution remains: Some analysts argue the bull case needs more proof despite the beat — concerns on sustainability of licensing revenue, product demand and execution could cap multiple expansion. Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.